GW Pharmaceuticals Appoints CFO, Adds UK Director

Scott Giacobello has been appointed chief financial officer at GW Pharmaceuticals, reporting to chief executive officer Justin Gover. Mr. Giacobello will be based at the company’s U.S. headquarters in Carlsbad, CA. He succeeds Adam George, who will serve as managing director – UK, a newly-created executive role with leadership responsibilities for UK operations.

"These important leadership appointments reflect GW’s continuing evolution into a transatlantic commercial-stage biopharmaceutical company. Scott’s significant financial and accounting expertise will be a major asset to the organization as we make that shift," said Mr. Gover. "In addition, with Adam having served as CFO since 2012, his new UK role leverages the broad knowledge he has of our business and provides continuity of strong senior UK-based leadership, essential elements to our continued success."

Mr. Giacobello has 25 years of finance and operational experience. He is an accomplished executive who most recently and until its acquisition by Allergan, Inc. in late 2016, served as chief financial officer for Chase Pharmaceuticals Corp., a clinical stage biopharma company focused on the development and commercialization of treatments for neurodegenerative disorders. Previously, he held senior level finance positions at Allergan, Inc., most recently as vice president of Finance for Global R&D.

Mr. George will work to ensure UK operations achieve strategic and operating goals, which include pipeline development, manufacturing scale-up, and European commercialization. Mr. George will continue as company secretary and will support Mr. Giacobello through the CFO transition.